Novartis India

Who are the top shareholders of the Novartis India?

The top shareholder of Novartis India is Novartis AG, holding 70.68% of the shares, followed by Atul Limited with 1.52%, and individual investors who own 23.11%. Additionally, foreign institutional investors hold 0.19%, while mutual funds have negligible holdings.

The top shareholders of Novartis India include Novartis AG, which holds the largest stake at 70.68%. Other notable shareholders include Atul Limited, with a holding of 1.52%, and individual investors who collectively own 23.11% of the shares. Additionally, there are 17 foreign institutional investors (FIIs) holding a small portion of 0.19%, and mutual funds are represented by six schemes, although they hold 0.0%.

how big is Novartis India?

As of Jun 06, Novartis India Ltd has a market capitalization of 2,487.72 Cr, classifying it as a Small Cap company, with recent net sales of 356.28 Cr and a net profit of 100.90 Cr. Shareholder's funds are valued at 744.82 Cr, and total assets amount to 909.56 Cr.

Market Cap: As of Jun 06, Novartis India Ltd has a market capitalization of 2,487.72 Cr, classifying it as a Small Cap company.<BR><BR>Recent Quarterly Performance: For the latest 4 quarters, Novartis India reported Net Sales of 356.28 Cr and a Net Profit of 100.90 Cr. This data is based on Standalone financials.<BR><BR>Balance Sheet Snapshot: This is also Standalone data for the reporting period ending Mar'24. The Shareholder's Funds are valued at 744.82 Cr, and the Total Assets amount to 909.56 Cr.

When is the next results date for Novartis India?

No Upcoming Board Meetings

Who are in the management team of Novartis India?

As of March 2023, the management team of Novartis India includes C Snook (Chairman), Sanjay Murdeshwar (Vice Chairman & Managing Director), Shilpa Joshi (CFO), and several independent directors. This team is responsible for the company's governance and operational management.

As of March 2023, the management team of Novartis India includes the following individuals:<BR><BR>1. C Snook - Chairman (Non-Executive)<BR>2. Jai Hiremath - Independent Director<BR>3. Sandra Martryes - Independent Director<BR>4. Sanjay Murdeshwar - Vice Chairman & Managing Director<BR>5. Sanker Parameswaran - Independent Director<BR>6. Nikhil Malpani - Company Secretary & Compliance Officer<BR>7. Shilpa Joshi - Whole Time Director & Chief Financial Officer<BR><BR>This team plays a crucial role in the governance and operational management of the company.

Has Novartis India declared dividend?

Yes, Novartis India Ltd has declared a 500% dividend, amounting to ₹25 per share, with an ex-date of July 23, 2024. The dividend yield is 2.5%, and while recent returns have shown some volatility, the company has demonstrated strong long-term growth and returns.

Novartis India Ltd has declared a 500% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 500%<BR>- Amount per share: 25<BR>- Ex-date: 23 Jul 24<BR><BR>Dividend Yield: 2.5%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, Novartis India experienced a price return of -2.95%, with no dividend return, resulting in a total return of -2.95%.<BR><BR>Over the past year, the company had a price return of -0.8% and a dividend return of 2.33%, leading to a total return of 1.53%.<BR><BR>In the 2-year period, the price return was 36.87%, with a dividend return of 4.26%, culminating in a total return of 41.13%.<BR><BR>For the 3-year period, the price return stood at 69.86% and the dividend return at 7.48%, resulting in a total return of 77.34%.<BR><BR>In the last 4 years, Novartis India recorded a price return of 53.94% and a dividend return of 6.34%, yielding a total return of 60.28%.<BR><BR>Lastly, over the 5-year span, the company achieved a price return of 64.44% and a dividend return of 11.55%, which resulted in a total return of 75.99%.<BR><BR>Overall, Novartis India has declared a significant dividend, and while recent returns have shown some volatility, the longer-term performance reflects strong growth and returns, particularly from dividends.

Who are the peers of the Novartis India?

Novartis India's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, and others. In terms of management risk, growth, and capital structure, Novartis India has average ratings, with a 1-year return of -3.58%, better than Indoco Remedies but lower than its other peers.

Peers: The peers of Novartis India are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Indoco Remedies, Senores Pharma., SMS Pharma., and Amrutanjan Healt.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and Amrutanjan Healt, while Good management risk is found at Divi's Lab., Torrent Pharma, and SMS Pharma. Average management risk is noted for Novartis India, Indoco Remedies, and Syncom Formul., while Below Average management risk is present at Senores Pharma. Growth is Excellent for Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and Senores Pharma., while Good growth is seen at Novartis India. Below Average growth is reported for Divi's Lab., Torrent Pharma, Indoco Remedies, SMS Pharma., and Amrutanjan Healt, and the rest have Below Average growth. Capital Structure is Excellent for Sun Pharma.Inds., Divi's Lab., Cipla, Dr Reddy's Labs, and Amrutanjan Healt, Good for Torrent Pharma, Average for Novartis India, Indoco Remedies, and SMS Pharma., and Below Average for Senores Pharma.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Divi's Lab. at 51.69%, while the peer with the lowest is Indoco Remedies at -11.00%. Novartis India's 1-year return is -3.58%, which is higher than Indoco Remedies but lower than all other peers. Additionally, Indoco Remedies and SMS Pharma. have negative six-month returns.

What does Novartis India do?

Novartis India Ltd, a subsidiary of Swiss pharmaceutical company Novartis, manufactures and markets drugs in the Pharmaceuticals & Biotechnology sector. As of March 2025, it reported net sales of ₹839 Cr and a net profit of ₹293 Cr, with a market cap of ₹2,617 Cr.

Overview:<BR>Novartis India Ltd is a subsidiary of the Swiss pharmaceutical giant Novartis, engaged in the manufacturing and marketing of drugs and pharmaceutical products within the Pharmaceuticals & Biotechnology industry, categorized as a Small Cap company.<BR><BR>History:<BR>Incorporated on 13 December 1947, Novartis India Ltd has maintained its status as a subsidiary of Novartis. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 839 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 293 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: INR 2,617 Cr (Small Cap)<BR><BR>Key Metrics:<BR>P/E: 26.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 2.37% <BR>Debt-Equity: -0.83 <BR>Return on Equity: 12.85% <BR>Price to Book: 3.32 <BR><BR>Contact Details:<BR>Address: The Inspire BKC Part 601 & 701, Bandra Kurla Complex Bandra(E) Mumbai Maharashtra : 400051 <BR>Phone: 91-022-50243000 <BR>Email: india.investors@novartis.com <BR>Website: http://www.novartis.in

Is Novartis India technically bullish or bearish?

As of October 24, 2025, Novartis India is in a bearish trend with strong indications of weakness across multiple technical indicators, including the MACD, Bollinger Bands, and moving averages, showing no immediate signs of reversal.

As of 24 October 2025, the technical trend for Novartis India has changed from mildly bearish to bearish. The current stance is bearish with a strong indication of weakness. The weekly MACD is bearish, and both the weekly and monthly Bollinger Bands confirm a bearish outlook. Daily moving averages also indicate bearish momentum. The KST is bearish on both weekly and monthly time frames, while the Dow Theory shows no trend on the weekly but is mildly bearish on the monthly. Overall, the indicators suggest a continued bearish trend with no immediate signs of reversal.

How has been the historical performance of Novartis India?

Novartis India has experienced fluctuating financial performance, with net sales declining from INR 490.68 crore in March 2019 to INR 356.27 crore in March 2025, while operating profit significantly improved from INR 12.28 crore to INR 133.38 crore during the same period, indicating a recovery in profitability despite declining sales. Total assets and liabilities also decreased, reflecting reduced financial obligations.

Answer:<BR>The historical performance of Novartis India shows fluctuations in key financial metrics over the years, with notable trends in net sales, operating profit, and profit after tax.<BR><BR>Breakdown:<BR>Novartis India's net sales have seen a decline from INR 490.68 crore in March 2019 to INR 356.27 crore in March 2025, with a peak of INR 399.87 crore in March 2022. Total operating income followed a similar trend, decreasing from INR 490.68 crore in March 2019 to INR 356.27 crore in March 2025. Operating profit (PBDIT) has improved significantly, rising from INR 12.28 crore in March 2019 to INR 133.38 crore in March 2025, indicating a strong recovery in profitability. Profit before tax also increased from INR 85.77 crore in March 2019 to INR 130.42 crore in March 2025, while profit after tax showed a recovery from a loss of INR 3.72 crore in March 2022 to INR 100.90 crore in March 2025. The company's cash flow from operating activities improved from a negative INR 69 crore in March 2021 to INR 74 crore in March 2025, reflecting better operational efficiency. Total assets decreased from INR 1,052.90 crore in March 2020 to INR 932.33 crore in March 2025, while total liabilities also decreased from INR 1,052.90 crore in March 2020 to INR 932.33 crore in March 2025, indicating a reduction in financial obligations. Overall, Novartis India has shown a recovery in profitability and operational cash flow despite declining sales and total assets.

Is Novartis India overvalued or undervalued?

As of November 4, 2025, Novartis India is fairly valued with a PE ratio of 19.90, making it a more attractive investment compared to peers like Sun Pharma and Divi's Lab, despite its recent underperformance against the Sensex.

As of 4 November 2025, Novartis India's valuation grade has moved from expensive to fair, indicating a shift in its market perception. The company is currently fairly valued, with a PE ratio of 19.90, a Price to Book Value of 0.27, and a PEG ratio of 0.91. These ratios suggest that the stock is reasonably priced compared to its earnings growth potential.<BR><BR>In comparison to its peers, Novartis India stands out with a more favorable valuation than Sun Pharma, which has a PE ratio of 35.41, and Divi's Lab, which has a PE ratio of 78.59. Other peers like Dr. Reddy's Labs and Cipla are also attractive but at higher valuations of 17.36 and 22.35, respectively. While Novartis India has underperformed the Sensex over the past year with a return of -19.75% compared to the Sensex's 5.94%, its current valuation metrics suggest it may be a more appealing investment opportunity relative to its peers.

Are Novartis India Ltd latest results good or bad?

Novartis India Ltd's latest Q3 FY26 results are disappointing, with a 36.8% decline in net profit and a 7.63% drop in revenue, indicating operational challenges. The company's stock has also underperformed, raising concerns about its future profitability and growth.

Novartis India Ltd's latest results for Q3 FY26 indicate a significant decline in both revenue and net profit, which can be interpreted as negative performance. The company reported a net profit of ₹16.09 crore, down 36.8% quarter-on-quarter, and revenue of ₹85.90 crore, which is a decrease of 7.63% from the previous quarter. Additionally, the operating margin has compressed to 26.03%, marking the lowest level in recent quarters.<BR><BR>The overall picture suggests that Novartis India is facing operational challenges, including cost pressures and pricing difficulties in its core pharmaceutical business. The stock has also underperformed significantly, declining 12.23% over the past year while the broader market has gained. Given these factors, the latest results are generally viewed as disappointing and raise concerns about the company's ability to maintain profitability and growth in the near future.

Should I buy, sell or hold Novartis India Ltd?

Why is Novartis India Ltd falling/rising?

As of 31-Jan, Novartis India Ltd's stock price is declining at Rs 759.30, down 0.78%, and has lost 5.18% over the past three days. The stock is underperforming significantly with a 1-year return of -11.24%, attributed to poor financial results and low confidence from domestic mutual funds.

As of 31-Jan, Novartis India Ltd's stock price is falling, currently at Rs 759.30, reflecting a decrease of Rs 6.0 or 0.78%. The stock has been on a downward trend, having lost 5.18% over the past three days. Additionally, it is trading lower than its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a weak performance relative to its historical price trends.<BR><BR>The stock's performance has also been poor over various time frames, with a 1-year return of -11.24%, significantly underperforming the Sensex, which has gained 7.18% in the same period. Furthermore, the stock is close to its 52-week low, just 1.89% above Rs 744.95. <BR><BR>Negative financial results have contributed to this decline, particularly a significant drop in profit after tax (PAT) by 36.8% in the most recent quarter, alongside a decrease in net sales by 7.63%. The low participation from domestic mutual funds, holding only 0.01% of the company, suggests a lack of confidence in the stock's current valuation and future prospects.<BR><BR>Despite some positive indicators, such as a healthy long-term growth rate in operating profit and a fair valuation compared to peers, the overall sentiment remains bearish due to the recent poor performance and disappointing financial results.

Which are the latest news on Novartis India?